EirGenix Inc. (6589.TWO)
- Previous Close
64.40 - Open
65.00 - Bid 63.60 x --
- Ask 63.70 x --
- Day's Range
63.60 - 66.00 - 52 Week Range
52.70 - 100.50 - Volume
327,715 - Avg. Volume
340,738 - Market Cap (intraday)
19.259B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.46 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
127.50
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
www.eirgenix.comRecent News: 6589.TWO
View MorePerformance Overview: 6589.TWO
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6589.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6589.TWO
View MoreValuation Measures
Market Cap
19.47B
Enterprise Value
16.91B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
20.24
Price/Book (mrq)
2.20
Enterprise Value/Revenue
17.41
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-77.37%
Return on Assets (ttm)
-5.48%
Return on Equity (ttm)
-8.00%
Revenue (ttm)
971.19M
Net Income Avi to Common (ttm)
-751.42M
Diluted EPS (ttm)
-2.46
Balance Sheet and Cash Flow
Total Cash (mrq)
3.79B
Total Debt/Equity (mrq)
13.94%
Levered Free Cash Flow (ttm)
-1.31B